Altre lingue Hansa Biopharma AB

Azioni

HNSA

SE0002148817

Biotecnologia

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 12/11/2025			Variaz. 5gg	Var. 1 gen.
26,54 ^SEK	+0,68%		-12,70%	-32,30%

12/11	Hansa Biopharma AB - Special Call
10/11	Finserve Micro Cap in calo dell'1,34% a ottobre: le small cap svedesi sottoperformano rispetto ai titoli a maggiore capitalizzazione	FW

Altre lingue

Upcoming KOL Call today: Insights on clinical practice and imlifidase Phase 3 Results	12/11
Hansa Biopharma : 30 Oct 2025 - Interim report January-September 2025 Transcript	10/11
Hansa at Truist Securities, Stifel, and SEB Healthcare conferences	05/11
Hansa Biopharma (Q3 Update) - Europe Below Expectations, but the US Will Drive Value	03/11
Hansa Biopharma: Increase in number of shares and votes	31/10
Hansa Biopharma : 30 Oct 2025 - Interim report January-September 2025 Presentation	30/10
Hansa Biopharma : 30 Oct 2025 - Interim report January-September 2025 Report	30/10
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results	30/10
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	30/10
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results	29/10
Hansa Biopharma AB Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler-Najjar syndrome who are immune to AAV	13/10
Genethon and Hansa Biopharma Announces Data from Gnt-018-Ides Trial Supports Feasibility of Imlifidase as Pret Treatment for Patients with Crigler-Najjar Syndrome Who Are Immune to Aav	10/10
Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler-Najjar syndrome who are immune to AAV	10/10
Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV	10/10
Hansa Biopharma to host Q3 2025 interim results conference call	08/10
Hansa Biopharma participating in Optimum's 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025	07/10
Hansa Biopharma raises $71 million through directed share issue	02/10
Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm	02/10
Hansa Biopharma to Raise $60 Million via Directed Share Issue	02/10
Hansa Biopharma has carried out a directed share issue of 17 million shares, raising proceeds of approximately USD 71 million	02/10
Hansa Biopharma AB announces USD 60 million share issue	01/10
Hansa Biopharma intends to carry out a directed share issue of approximately USD 60 million	01/10
Hansa Biopharma AB - Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025	29/09
Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025	26/09
Genethon to Present Preliminary Efficacy and Safety Data from Phase 2 Trial of Imlifidase as A Pre-Treatment to GNT-0003 at ESGCT Congress 2025	26/09

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hansa Biopharma AB

Azioni

HNSA

SE0002148817

Biotecnologia

Altre lingue

Filtri